Insider Selling: Medpace Holdings, Inc. (NASDAQ:MEDP) CEO Sells 15,102 Shares of Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August J. Troendle sold 15,102 shares of the company’s stock in a transaction dated Monday, April 29th. The stock was sold at an average price of $400.69, for a total transaction of $6,051,220.38. Following the completion of the sale, the chief executive officer now directly owns 791,541 shares in the company, valued at $317,162,563.29. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Medpace Stock Up 2.4 %

Shares of NASDAQ:MEDP opened at $397.86 on Thursday. The firm’s 50 day moving average price is $398.32 and its 200-day moving average price is $328.94. Medpace Holdings, Inc. has a twelve month low of $197.39 and a twelve month high of $421.00. The stock has a market capitalization of $12.33 billion, a PE ratio of 40.56, a price-to-earnings-growth ratio of 1.93 and a beta of 1.40.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, April 22nd. The company reported $3.20 EPS for the quarter, topping analysts’ consensus estimates of $2.45 by $0.75. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The company had revenue of $511.00 million for the quarter, compared to analysts’ expectations of $512.39 million. During the same quarter last year, the business earned $2.27 EPS. The firm’s revenue was up 17.7% compared to the same quarter last year. Analysts expect that Medpace Holdings, Inc. will post 11.23 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Medpace

A number of institutional investors have recently added to or reduced their stakes in MEDP. IFP Advisors Inc grew its holdings in Medpace by 144.3% during the 3rd quarter. IFP Advisors Inc now owns 171 shares of the company’s stock valued at $41,000 after buying an additional 101 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of Medpace by 353.2% in the third quarter. SG Americas Securities LLC now owns 2,515 shares of the company’s stock valued at $609,000 after purchasing an additional 1,960 shares in the last quarter. Commonwealth Equity Services LLC grew its holdings in shares of Medpace by 20.2% in the third quarter. Commonwealth Equity Services LLC now owns 2,765 shares of the company’s stock valued at $669,000 after purchasing an additional 465 shares in the last quarter. Cambridge Investment Research Advisors Inc. grew its holdings in shares of Medpace by 13.3% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 3,755 shares of the company’s stock valued at $909,000 after purchasing an additional 440 shares in the last quarter. Finally, FinTrust Capital Advisors LLC purchased a new position in shares of Medpace in the third quarter valued at $30,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently weighed in on MEDP shares. Deutsche Bank Aktiengesellschaft started coverage on shares of Medpace in a research report on Monday, March 18th. They issued a “hold” rating and a $395.00 target price on the stock. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and upped their target price for the stock from $340.00 to $450.00 in a research report on Tuesday, April 23rd. UBS Group raised shares of Medpace from a “neutral” rating to a “buy” rating and increased their price objective for the company from $282.00 to $452.00 in a research report on Thursday, February 15th. StockNews.com raised shares of Medpace from a “hold” rating to a “buy” rating in a research report on Tuesday, April 23rd. Finally, Robert W. Baird increased their price objective on shares of Medpace from $446.00 to $454.00 and gave the company an “outperform” rating in a research report on Wednesday, April 24th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $443.00.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.